No 'Safe Harbor' For Gene Therapy Found In Hatch-Waxman

By Andrew Karpan · January 4, 2022, 9:44 PM EST

A Delaware federal judge told Massachusetts biotechnology company Sarepta on Tuesday that it could not use the "safe harbor" provisions of the Hatch-Waxman Act to protect a gene therapy it is...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

REGENXBIO Inc. et al v. Sarepta Therapeutics, Inc., et al.

Case Number

Court

Delaware

Nature of Suit

Patent

Date Filed

September 15, 2020

Recent Articles By Andrew

November 22, 2024
Wellness Software Co. Not Immune From IP Suit, Judge Says
November 19, 2024
Judge Rejects Infosys' Bid To Seal NDAs In Trade Secrets Row
November 18, 2024
Melinta Obtains Ban On Generic Antibiotic Injections In IP Row
November 12, 2024
GOP Reps. Propose Another Bill On TRIPS Waivers
October 23, 2024
Court Denies Fees In 'Objectively Specious' Trade Secrets Suit
October 02, 2024
Avadel Tells Fed. Circ. It Should Be Free To Test Sleep Drug
September 26, 2024
2nd Circ. Denies Jury Trial In Abbott Labs Gray Market Case
September 09, 2024
Purdue Sees Another OxyContin Patent Axed
September 05, 2024
Nvidia, Microsoft Face Patent, Cartel Allegations In Texas Suit
August 09, 2024
Valeant's Legal Gripe A Total 'Nothingburger,' Justices Told